TransForm, J&J and topiramate: New life, old products

In May, the US Patent Office granted TransForm its first patent on topiramate sodium trihydrate-an alternate salt form of J&J's $700 million epilepsy drug Topamax. J&J found itself with an interesting complement to Alza reformulation efforts on the drug--which were gearing it for alternative indications like obesity and migraine--and a potential IP complication. The business-like result: a broad licensing agreement under which TransForm assigns all its topiramate patent rights to J&J in exchange for up-front money, an equity investment, milestones, and future royalties.

When Johnson & Johnson acquired Alza Corp. [See Deal] one of the objectives of this $13 billion acquisition was to apply the drug delivery company's technology to its own pipeline—improving existing products or resurrecting compounds. One project prominently mentioned by both Alza and J&J: expanding the uses for topiramate (Topamax), J&J's $700 million epilepsy drug, particularly as an obesity treatment. In the high doses required for an obesity drug, Topamax wasn't well tolerated, causing such adverse events as fatigue and abnormal vision. The idea was to have Alza create a controlled-release version of the drug to see if it could optimize performance.

Meanwhile chemists from the form and formulations start-up TransForm Pharmaceuticals Inc. had already begun generating novel crystalline forms of the drug and filing patents on them. (See "The New...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.